Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Exppra 500 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Exppra 500

Approved

STANDARD

Exppra 500

Exemed Pharmaceuticals🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: c109547714f91b4d
Company: Exemed Pharmaceuticals
Type: Standard

Approval Details

Approval Id: c109547714f91b4d
Drug Approval Philippines Name: Exppra 500
Product Name: Exppra 500
Registration Number: DRP-15773
Brand Name: Exppra 500
Generic Name: Levetiracetam
Dosage Form: Film-Coated Tablet
Dosage Strength: 500 mg
Manufacturer: Exemed Pharmaceuticals
Importer: Saifen Drugs Philippines, Inc.
Distributor: Saifen Drugs Philippines, Inc.
Company Detail Path: /organization/exemed-pharmaceuticals
Issuance Date: 15 September 2024
Expiry Date: 01 August 2029
Pharmacologic Category: Antiepileptic
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

c109547714f91b4d

Type

Standard

Back to Philippines FDA Approvals